3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Cisplatin
53
Paclitaxel
27
Carboplatin
22
Brachytherapy
18
Radiotherapy
17
human papillomavirus vaccine, L1 type 16, 18
12
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
12
Gemcitabine
12
Topotecan
8
Vaccines, Synthetic
7
Platinum
7
Papillomavirus Vaccines
7
Radiation
6
Bevacizumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
Neoadjuvant Therapy
5
Chemotherapy, Adjuvant
5
pembrolizumab
4
Vinorelbine
4
Radiotherapy, Intensity-Modulated
4
Pemetrexed
4
Drug Therapy
4
Taxes
3
Surgical Procedures, Operative
3
Ondansetron
3
Irinotecan
3
Dexamethasone
3
Chemoradiotherapy
3
tisotumab vedotin
2
specific substance maruyama
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Uterine Cervical Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled